CoChat

Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Open access
Shaffer, Arthur L., Phelan, James D., Wang, James Q., Huang, DaWei, Wright, George W., Kasbekar, Monica, Choi, Jaewoo, Young, Ryan M., Webster, Daniel E., Yang, Yandan, Zhao, Hong, Yu, Xin, Xu, Weihong, Roulland, Sandrine, Ceribelli, Michele, Zhang, Xiaohu, Wilson, Kelli M., Chen, Lu, McKnight, Crystal, Klumpp-Thomas, Carleen, Thomas, Craig J., Häupl, Björn, Oellerich, Thomas, Rae, Zachary, Kelly, Michael C., Ahn, Inhye E., Sun, Clare, Gaglione, Erika M., Wilson, Wyndham H., Wiestner, Adrian, Staudt, Louis M. · 2021 · Blood Cancer Discovery
Cited by 61

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

The use of Bruton tyrosine kinase (BTK) inhibitors to block B-cell receptor (BCR)–dependent NF-κB activation in lymphoid malignancies has been a major clinical advance, yet acquired therapeutic resistance is a recurring problem. We modeled the development of resistance to the BTK inhibitor ibrutinib in the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma, which relies on chronic active BCR signaling for survival. The primary mode of resistance was epigenetic, driven in part by the transcription factor TCF4. The resultant phenotypic shift altered BCR signaling such that the GTPase RAC2 substituted for BTK in the activation of phospholipase Cγ2, thereby sustaining NF-κB activity. The interaction of RAC2 with phospholipase Cγ2 was also increased in chronic lymphocytic leukemia cells from patients with persistent or progressive disease on BTK inhibitor treatment. We identified clinically available drugs that can treat epigenetic ibrutinib resistance, suggesting combination therapeutic strategies. Significance: In diffuse large B-cell lymphoma, we show that primary resistance to BTK inhibitors is due to epigenetic rather than genetic changes that circumvent the BTK blockade. We also observed this resistance mechanism in chronic lymphocytic leukemia, suggesting that epigenetic alterations may contribute more to BTK inhibitor resistance than currently thought. See related commentary by Pasqualucci, p. 555. This article is highlighted in the In This Issue feature, p. 549

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2643-3230.bcd-21-0063

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 61

Metadata

Authors
Shaffer, A. L., Phelan, J. D., Wang, J. Q., Huang, D., Wright, G. W., Kasbekar, M., Choi, J., Young, R. M., Webster, D. E., Yang, Y., Zhao, H., Yu, X., Xu, W., Roulland, S., Ceribelli, M., Zhang, X., Wilson, K. M., Chen, L., McKnight, C., Klumpp-Thomas, C., Thomas, C. J., Häupl, B., Oellerich, T., Rae, Z., Kelly, M. C., Ahn, I. E., Sun, C., Gaglione, E. M., Wilson, W. H., Wiestner, A., & Staudt, L. M.
Venue
Blood Cancer Discovery
Published
2021-09-14
Volume
2
Issue
6
Pages
630-647
ISSN
  • 2643-3230 (ISSN-L)
  • 2643-3249
OpenAlex
W3199949813
Cited by
61
References
27
FWCI
4.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. https://app.cochat.ai/papers/10.1158/2643-3230.bcd-21-0063
The paper
Shaffer, A. L., Phelan, J. D., Wang, J. Q., Huang, D., Wright, G. W., Kasbekar, M., Choi, J., Young, R. M., Webster, D. E., Yang, Y., Zhao, H., Yu, X., Xu, W., Roulland, S., Ceribelli, M., Zhang, X., Wilson, K. M., Chen, L., McKnight, C., . . . Staudt, L. M. (2021). Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. Blood Cancer Discovery. https://doi.org/10.1158/2643-3230.bcd-21-0063

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.